Our Revolutionary Science
Actym has developed a novel, systemically administered therapeutic platform that can overcome the tumor immune microenvironment, which is hostile to T-cells. Our platform is based on a gene edited, immunologically cloaked microbe capable of enriching in solid tumors. Once there, multiplexed immuno-modulatory payloads are delivered directly to tumor-resident, antigen-presenting cells which allows for the multinodal targeting of the cancer immunity cycle.
More About Our Technology